FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 137 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... February 22, 2024 How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... October 12, 2023 Workout Wednesday – Upper Body Stretches July 1, 2020 Beloved Jeopardy! Host Alex Trebek Has Passed Away After Battle with... November 9, 2020 Load more HOT NEWS Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for... Trial Establishes Preferred Treatment for Some People with Esophageal Cancer Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours Giving Myself the Most Time and Best Chance at Beating Cancer:...
